PHILADELPHIA, April 7, 2021 /PRNewswire/ — Enterin, Inc., a clinical-stage biopharmaceutical firm pioneering novel remedies for neurodegenerative illnesses, pronounces the appointment of Donald Munoz to its Board of Administrators.
“We’re thrilled to welcome Don to Enterin’s Board,” stated David McCullough, Enterin’s Chief Government Officer. “He brings important biotechnology trade experience and super monetary expertise given his roles as a public-company CFO and healthcare funding banker. Don can be an excellent companion to the manager staff as Enterin enters its subsequent section of progress.”
Enterin’s Board Chairman Jay Brammer added, “We stay up for working with Don and I’m assured he’ll make sturdy contributions to the success of Enterin.”
“I’m excited to hitch Enterin’s Board and work with the staff to advance our compounds by way of medical improvement,” stated Don Munoz. “Enterin’s compounds signify a novel and extremely promising strategy towards the therapy of neurodegenerative illnesses, and I stay up for contributing to the Firm’s success.”
Munoz presently serves as Chief Monetary Officer of NuCana plc, a Nasdaq-listed biotechnology firm targeted on considerably enhancing therapy outcomes for sufferers with most cancers. NuCana accomplished a $114 million IPO in 2017 and an $80 million follow-on providing in 2020. Previous to becoming a member of NuCana in 2015, Don served as Group Chief Monetary Officer of NOXXON Pharma. He has an in depth monetary background with roughly 20 years as a healthcare funding banker at Alex. Brown & Sons, Deutsche Financial institution, Leerink Companions and Cowen. Don has accomplished over 100 financing and merger and acquisition transactions with an mixture worth of greater than $30 billion. He acquired an MBA in Finance and Accounting from Columbia Enterprise Faculty, the place he was elected to Beta Gamma Sigma, and an AB in Psychology from Dartmouth Faculty.
Enterin is growing novel compounds that restore the dysfunctional gut-brain axis to deal with sufferers with neurodegenerative illnesses. Enterin is pioneering the medical neighborhood’s understanding of the hyperlink between infections, dysfunction of the enteric nervous system (ENS) and the early signs and development of neurodegenerative illnesses. Enterin’s lead compound, ENT-01, has been proven to displace membrane-bound alpha-synuclein (αS) aggregates from nerve cells within the ENS and enhance neural signaling between the intestine and the mind in preclinical fashions of Parkinson’s illness and in human research. ENT-01 is presently in a 150-patient, placebo-controlled Part IIb medical research designed to display its potential to reverse the neurological signs of Parkinson’s illness. Enterin’s second compound, ENT-03, is designed to reverse central insulin resistance, a key pathology in illnesses similar to weight problems, diabetes, and Alzheimer’s illness. ENT-03 is predicted to enter a Part I research in 2022.
For extra info, please go to www.enterininc.com.
SOURCE Enterin Inc.